Racial and ethnic disparities exist in the incidence of both hypertension and diabetes in the United States. 1 Blacks and Hispanics are at the highest risk for these conditions. 1 Hypertension frequently coexists with diabetes, and patients with the comorbidity may be at 2-fold or greater risk for cardiovascular disease (CVD) or death compared with those with hypertension or diabetes alone. 2, 3 In a recent study of Framingham participants with diabetes, the presence of hypertension was a strong driver of mortality, and was associated with a 72% increase in risk of all-cause death. 4 The higher age-adjusted CVD death rates among blacks vs. others have been attributed to differences in prevalence of CVD risk factors (including hypertension) and related to access to care. 5, 6 CVD is also the leading cause of death among US Hispanics. 1 Compared with whites, Hispanics with hypertension may experience lower rates of awareness, treatment, and control; 7 these and other factors may contribute to higher rates of preventable hospital readmissions. 8 Utilization of evidence-based cardiovascular/antihypertensive therapies is associated with reduced risk of CVD events and mortality, 9,10 suggesting that interventions that improve access and adherence to preventive therapies have the potential to significantly reduce disparities in CVD outcomes. Differential uptake of cardiovascular/antihypertensive therapies among black and Hispanic patients vs. others with hypertension and diabetes may contribute to differences observed in clinical outcomes. However, data from realworld settings to evaluate this are limited. The purpose of this study was to evaluate the association between race/ethnicity and rehospitalization or death, accounting for cardiovascular/antihypertensive therapy, among a cohort of patients with hypertension and diabetes hospitalized for CVD.
METHODS

Study design and population
This was a 1-year prospective study of hospitalized patients with hypertension and diabetes who participated in the National Heart, Lung, and Blood Institute-sponsored Family Cardiac Caregiver Investigation to Evaluate Outcomes (FIT-O) Study. The design and methods of FIT-O have been previously described. 11, 12 Briefly, FIT-O was an observational study designed to evaluate patterns of caregiving among cardiac patients and the association between having a caregiver and clinical outcomes of consecutively admitted cardiovascular service inpatients at a university medical center (93% enrollment rate; n = 4,500). 12 Patients were excluded from participation if (i) they were unable to read or understand English or Spanish; (ii) they lived in a full-time nursing facility; (iii) mental status precluded participation; or (iv) they refused to participate.
This study included FIT-O participants with physiciandocumented hypertension and diabetes and with race/ethnicity listed in their electronic medical records. The study was approved by the institutional review board of Columbia University Medical Center.
Baseline measures
Participant medical records were accessed by a secure and comprehensive electronic clinical information system. Race/ ethnicity (white, black, Hispanic, Asian, Native American, Pacific Islander, not reported/unknown) and other demographic variables (age, sex, health insurance), prescription medications, smoking status, and medical history were documented by standardized electronic chart review. Race/ ethnicity, age, sex, and health insurance status were obtained from patient self-reported registration data. Prescribed medications and documented medication contraindications were obtained from admission and discharge notes and supplemented by the ambulatory electronic records. Current and prior medical conditions, including hypertension, diabetes, renal failure, peripheral vascular disease, heart failure, stroke, coronary heart disease, and chronic obstructive pulmonary disease, were determined using International Classification of Disease, Ninth Revision billing codes and physician or nurse practitioner notes. Caregiver status (i.e., having a paid professional or informal (nonpaid) person who assists the patient with medical and/or preventive care), which we have previously shown to be associated with rehospitalization, 12, 13 was assessed by standardized questionnaire administered to each participant at baseline. Admission type was categorized as surgical (cardiac) vs. nonsurgical CVD admission. All research staff members were Health Insurance Portability and Accountability Act trained and certified in the use of the clinical information system.
Clinical outcomes
The primary clinical outcome was odds of rehospitalization within 1 year among black and Hispanic participants vs. whites/others, accounting for cardiovascular/ antihypertensive medication prescription. Secondary outcomes were (i) rehospitalization at 30 days and (ii) death at 1 year or at 30 days. Rehospitalization was systematically obtained using the hospital electronic clinical information systems, which were updated daily. To supplement outcomes data obtained by electronic medical records, participants were systematically contacted by mail or telephone 1 year after the index hospitalization that corresponded with their baseline survey interview date. These participants were queried regarding rehospitalization at the medical center or elsewhere in the prior year (82% response rate). This definition of rehospitalization yielded results similar to analyses limited to readmission to the medical center only. 12 Vital status/death dates were obtained using the clinical information system, which was updated monthly with National Death Index data. To minimize the chance of missing data, vital status/death dates were accessed from the system 6 months after each participant's 1-year follow-up date.
Statistical analysis
Descriptive data are presented as frequencies and percentages. Race/ethnic group was categorized as black, Hispanic, or white/other. Prescription cardiovascular/antihypertensive medications were categorized as (i) angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) vs. no ACE/ARB; (ii) beta-blocker vs. no betablocker; (iii) calcium channel blocker vs. no calcium channel blocker; and (iv) diuretic vs. no diuretic. Health insurance status was defined as no health insurance vs. having health insurance (any type). Caregiving was categorized as having paid, informal, or any (either paid or informal) caregivers vs. no caregiver. Admission type was categorized as surgical (cardiac) vs. nonsurgical. Χ 2 statistics were performed to determine the associations between race/ethnic group and cardiac/antihypertensive medication prescription, demographic characteristics, comorbidities, and outcomes. Participants who were rehospitalized and died were included in estimates for both outcomes. Odds ratios were calculated to estimate the effect size of associations. Analyses excluding participants with documented contraindications to select classes of antihypertensive medications yielded similar results to analyses retaining all participants. Therefore results include the entire study population. The independent association between race/ethnic group and clinical outcomes, adjusted for prescription medications and covariables, was estimated using logistic regression. Logistic regression models were built in 3 stages: (i) a model that includes race/ethnicity plus discharge medication significantly associated with the outcome in univariable analysis (model 1); (ii) model 1 plus clinically relevant demographic factors (sex, aged ≥65 years, heath insurance, having a caregiver) (model 2); (iii) model 2 plus clinically relevant comorbid conditions (renal failure/dialysis, peripheral vascular disease, chronic obstructive pulmonary disease, heart failure, stroke, coronary heart disease, smoking, and cardiac surgery admission) (model 3). The associations between race/ethnicity and medications prescribed (before admission and at discharge) were evaluated using logistic regression adjusting for the demographic factors and comorbid conditions listed in model 3. Goodness-of-fit was assessed using the Hosmer-Lemeshow test for each model. Analyses were conducted using SAS software (version 9.3; SAS Institute, Cary, NC). Statistical significance was set at P < 0.05.
RESULTS
Study sample
Among 1,205 FIT-O participants with documented hypertension and diabetes, 79 (6.5%) had no documented race/ethnicity and were excluded from the study (study n = 1,126; 14% black (n = 161), 28% Hispanic (n = 317), and 52% white (n = 582)/Asian (n = 65)/Pacific Islander (n = 1)). Participants excluded because of missing race/ethnicity data did not significantly differ from included participants based on age, sex, or prescription of antihypertensive medication at discharge. Excluded participants were less likely to have health insurance and were more likely to have a diagnosis of heart failure or stroke.
The characteristics of the study population are summarized in Table 1 . Compared with whites/others, black and Hispanic participants were more likely to be women, aged <65 years old, or to lack health insurance. Hispanics were more likely than blacks were to lack health insurance. Whites/others were more likely than Hispanics to have chronic obstructive pulmonary disease, coronary heart disease, or to be admitted for cardiac surgery procedure.
Associations between race/ethnicity and prescribed antihypertensive medications
The majority of participants (93%) reported having a prescription for cardiovascular/antihypertensive medication(s) before admission. This did not vary among black (94%), Hispanic (91%), or white/other participants (93%; P = 0.50; data not shown). Black participants were more likely than whites/others to be prescribed an ACE inhibitor/ARB (odds ratio (OR) = 1.6; 95% confidence interval (CI) = 1.1-2.3) or a calcium channel blocker (OR = 1.6; 95% CI = 1.1-2.3). Hispanic participants were less likely than whites/others to be prescribed a beta-blocker before admission (OR = 0.6; 95% CI = 0.4-0.8).
At discharge, 96% of participants were prescribed a cardiovascular/antihypertensive medication, and this did not vary among black (98%), Hispanic (94%), or white/other (96%; P = 0.10; data not shown) participants. Black participants were more likely than whites/others (OR = 1.9; 95% CI = 1.3-2.7) to be prescribed a calcium channel blocker at discharge.
In multivariable analysis, lower odds of beta-blocker prescription before admission among Hispanics vs. whites/others were significant after adjustment for demographic and comorbid conditions (OR = 0.5; 95% CI = 0.4-0.7; data not shown). The higher odds of ACE inhibitor/ARB prescription before admission among black vs. white/other participants were not significant after adjustment. The associations between black vs. white race/ethnicity and increased odds of calcium channel blocker prescription before admission and at discharge retained magnitude and statistical significance after adjustment for demographic and comorbid conditions (OR = 1.6, 95% CI = 1.1-2.4; OR = 1.9, 95% CI = 1.3-2.7, respectively; data not shown).
Associations between race/ethnicity and clinical outcomes
The associations between race/ethnicity and rehospitalization at 1 year and at 30 days are shown in Table 2 . Of 1,126 participants, 611 (54%) were rehospitalized within the year after their admission. Compared with whites/others, Hispanic participants were more likely to be rehospitalized at 1 year (63% vs. 50%; P = 0.0001; data not shown). Increased odds of rehospitalization at 1 year among blacks compared with whites/others was not statistically significant (57% vs. 50%; P = 0.11; data not shown). Hispanics were not more likely to be rehospitalized compared with blacks at 1 year (63% vs. 57%; P = 0.19; data not shown). Discharge prescription of a diuretic was associated with higher odds of rehospitalization at 1 year compared with no diuretic prescription. Additional participant characteristics associated with increased odds of rehospitalization at 1 year were lack of heath insurance, having a caregiver, and comorbid conditions, including peripheral vascular disease and heart failure. At 30 days, 11% (n = 129) of participants had been rehospitalized. Odds of rehospitalization did not significantly differ by race/ethnic group (Table 2) . Diuretic prescription and heart failure were each associated with higher odds of rehospitalization at 30 days.
At 30 days, 28 (2%) participants had died. This did not vary among black (n = 3; 2%), Hispanic (n = 10; 3%), or white/ other participants (n = 15; 2%; P = 0.63; data not shown). At 1 year, 108 (10%) participants had died. There was no significant association between black or Hispanic vs. white race/ ethnicity and death at 1 year (OR = 1.2, 95% CI = 0.7-2.1; OR = 0.8, 95% CI = 0.5-1.3, respectively; data not shown).
In multivariable models, the association between Hispanic ethnicity and rehospitalization at 1 year retained statistical significance after adjustment for discharge medication, demographic factors, and comorbid conditions (Table 3) . Additional multivariable predictors of rehospitalization or death at 1 year included prescription of a diuretic at discharge and heart failure.
DiSCUSSiON
One year after hospitalization for CVD, more than half of this cohort of patients with hypertension and diabetes had been rehospitalized. Approximately 1 in 10 died. Compared with whites/others, Hispanic patients were more likely to be rehospitalized at 1 year. A similar association was observed among black vs. white/other participants, but this was not statistically significant. This ethnic difference in odds of rehospitalization at 1 year was not observed at 30 days and was not fully explained by class of prescribed medication or other measured factors. More than 95% of participants in this study were prescribed cardiovascular/antihypertensive medication at discharge. This did not differ by race/ethnicity. However, there were significant differences in class of medications prescribed.
The higher frequency of calcium channel blocker prescription among black participants is consistent with current treatment guidelines recommending calcium channel blockers as a first-line of therapy among black patients with hypertension. 9 Differences in prescription for beta-blockers before admission among Hispanics vs. whites/others persisted after adjustment for comorbidity, including coronary heart disease. This suggests variation in prescription patterns or in adherence before admission by race/ethnicity may exist.
Black and Hispanic patients were more likely than whites/ others to lack health insurance, potentially impacting longterm adherence to prescribed medication. However we were unable to directly measure this. Hispanic participants were more likely than black participants to lack health insurance, which could have contributed to increased rehospitalization rates. Recent research by Wang et al. documented lower medication cost expenditures among Hispanic vs. white patients with hypertension, independent of overall health status and health insurance coverage. This suggests that prescription medication adherence patterns may also differ among Hispanics vs. others. 14 We observed higher odds of death or rehospitalization among Hispanic patients compared with whites/others at 1 year but not at 30 days. A similar pattern among black vs. whites that was not statistically significant was also observed. This difference in race/ethnic disparities in long-term vs. short-term risk has also been observed among diabetes and hypertension patients in other settings and attributed to differences in outpatient management and chronic disease burden. 15, 16 In our study, the significant link between Hispanic ethnicity and rehospitalization was attenuated after adjustment for lack of health insurance, underscoring the potential impact that differential chronic disease incidence and management may contribute to clinical outcomes. Among >7,000 insured adults with diabetes participating in the Translating Research Into Action for Diabetes study, there were few racial/ethnic disparities in care observed in the managed care setting, suggesting fewer financial barriers may contribute to equalized care. 17 Moreover, our results parallel recent findings by Lauffenburger et al., who documented no significant race/ethnic differences in medication adherence to ACE inhibitors, ARBs, or beta-blockers among Medicare beneficiaries 30 days after acute cardiac admission but documented lower adherence among Hispanic and black patients vs. whites/others at 12 months. 18 The inconsistency of 30-day and 1-year outcomes observed in our study and in others may be important. Circumstances such as access and adherence to medications and treatment may change after the initial 30 days after discharge, when adherence may be higher. 19 Strengths of our study include the racially/ethnically diverse male and female study population and longer-term (1-year) follow-up, including mortality data collected in a real-world setting. One limitation of this study was the use of medical records to ascertain participant race/ethnicity. These data were limited by lack of information to estimate the proportion of Hispanic participants who were also black. We also did not measure medication adherence. Therefore inferences about it as a contributing factor to differential outcomes cannot be determined. Social determinants may be significant contributors to racial/ethnic disparities in outcomes at 1 year, but we were not able to assess this. Unmeasured potential confounders associated with race and medication adherence, such as health literacy, language barriers, and race consciousness, could have contributed to observed associations. [20] [21] [22] Lower sample size of black participants may have limited our power to detect a statistically significant difference in rehospitalization rate between blacks and others at 1 year.
Black and Hispanic race/ethnicity are associated with increased cardiovascular disease risk factors and adverse clinical outcomes in the general population. 1 However, it was unknown whether this disparity persisted in a high-risk population after cardiovascular hospitalization. It was also not known whether it relates to uptake of cardiovascular/antihypertensive medication. In this study of hospitalized hypertension patients with diabetes, higher odds of rehospitalization Reference group is no prescription for specified class.
among Hispanics were observed at 1 year but not at 30 days. Reasons for the difference remain unclear, but are not explained by differences in prescription rates or types of antihypertension therapy at discharge. The inconsistency in disparities at 1 year and at 30 days suggests unmeasured factors (e.g., social, access to care, medical adherence) should be explored in future studies. Research to evaluate the links between race/ethnicity, adherence to medical recommendations, and outcomes may further clarify the mechanisms linking race/ethnicity to rehospitalization and may lead to the development of interventions to reduce disparities and improve outcomes among high-risk cardiovascular patients.
